Furthermore, STZ treatment increased Tau level (intensity: 114%–117%, p = .002–<.001; area: 202%–197%, p < .001) in the hippocampus and cortex of 3 × Tg‐AD mice (STZ group), whereas LM‐031 treatment could decrease the level of Tau (intensity: 101%–104%, p = .006–<0.001; area: 141%–113%, p < .001) (STZ/LM‐031 group) compared to the normoglycemic control (– STZ group, 100%) (Figure 5b). Here, MAPT is linked to Alzheimer disease.